Background {#Sec1}
==========

There are different reasons why children and adolescents with inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH) underlie a high risk for severe infections. First, those diseases are immune-mediated; thus, the disease itself is responsible for changes in immune reactions. Secondly, the treatment of immune-mediated diseases requires pharmacological immunosuppression (IS) \[[@CR1]--[@CR3]\]. Moreover, the rates of vaccination are not always high enough to ensure herd immunity for immunosuppressed children \[[@CR4]\]. Thus, young patients with IBD and AIH lacking vaccinations are at higher risk for severe infections with for example varicella \[[@CR5]\].

Vaccinations with live vaccines, as varicella and measles vaccines, are currently not recommended in patients receiving IS therapy. The main reasons are safety concerns due to a lack of data showing a sufficient reaction to the vaccination without higher complication rates. Thus, vaccinations are suggested to be administered before starting IS therapy or therapy should be interrupted during remission of the disease \[[@CR6]\]. However, already at diagnosis, IS therapy needs to be started and IS interruption is often impossible for satisfying disease control.

The ability of the adaptive immune system to react adequately on viral infections or vaccinations depends on a functional B and T lymphocyte compartment.

Vaccine-induced effectors are antibodies produced by B lymphocytes capable of binding toxin or antigen and cytotoxic CD8+ T lymphocytes (CTL) that recognize and kill infected cells \[[@CR7]\]. Thus, activation of T and B lymphocytes by activated dendritic cells and monocytes is the initial step of a vaccine response. Besides the predominant role of B cells during this process, the importance of T cell response is evident: T cells are essential for the induction of high-affinity antibodies and immune memory. Determination of the altered immune competence in patients receiving immunosuppressive drugs depends on the general condition and the degree and mode of action of the immunosuppressive medication \[[@CR8]\].

A proliferation assay is a simple in vitro method of measuring lymphocyte activation and proliferation ability. Lymphocytes can be artificially stimulated using unspecific mitogens, e.g., phytohemagglutinin (PHA) or antigens that induce specific recall T cell responses either through natural exposure (adenovirus antigen) or as a result of vaccination (tetanus antigen).

Therefore, it is important to examine the individual immunoreactivity in children and adolescents with IBD and AIH to provide a deeper insight in the functional capability of the cellular immune system under different regimes of IS therapy. This may influence the decision on vaccinations during IS therapy with live vaccines in these patients.

Methods {#Sec2}
=======

We collected blood samples of 31 patients aged 3 to 18 years treated in the pediatric gastroenterology of Ulm University Medical Center as part of the VARICED study investigating varicella vaccination in immunosuppressed patients with IBD (according to the ethics approval by the ethics committee, University of Ulm, number 214/2013). Sixteen of them are female, and 15 are male. Sixteen patients have Crohn's disease (CD), 12 ulcerative colitis (UC), and 3 AIH (see Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsGroupGenderAgeDiagnosisAge at diagnosisIS1f9CD3Sirolimus 0.1 mg/kg/day\
(10.4 ng/ml blood level)1m14UC11Vedolizumab 300 mg/8 weeks1m17UC15Adalimumab 40 mg/week\
(11.57 μg/ml blood level)1f12CD8Adalimumab 40 mg/week\
(10.35 μg/ml blood level)1m16CD3Adalimumab 40 mg/2 weeks\
(6.5 μg/ml blood level)1m14UC12Adalimumab 40 mg/week\
(12.35 μg/ml blood level)\
Tacrolimus 0.12 mg/kg/day\
(2.6 ng/ml blood level)\
AZA 1.0 mg/kg/day1f11UC10Infliximab 5 mg/kg/4 weeks\
(4.66 μg/ml blood level)1f18UC17Vedolizumab 300 mg/8 weeks\
AZA 2.6 mg/kg/day\
Sirolimus 0.18 mg/kg/day\
(8.8 ng/ml blood level)\
Prednisolone 0.5 mg/kg/day1f15UC10Adalimumab 40 mg/4 weeks\
(6.5 μg/ml blood level)1m5CD3Infliximab 10 mg/kg/4 weeks\
(0.5 μg/ml blood level)\
Tacrolimus 0.19 mg/kg/day\
(30.9 ng/ml blood level)1f14CD13Infliximab 5 mg/kg/4 weeks\
(3.36 μg/ml blood level)1m14CD13Infliximab 5 mg/kg/6 weeks\
(1.56 μg/ml blood level)\
AZA 2.1 mg/kg/d1m9UC6Infliximab 5 mg/kg/6--8 weeks\
(1.03 μg/ml blood level)\
AZA 2.2 mg/kg/day1f10UC5Vedolizumab 250 mg/8 weeks1m12CD12Infliximab 5 mg/kg/8 weeks\
(0.94 μg/ml blood level)1m11CD4Golimumab 50 mg/4 weeks\
(8.5 μg/ml blood level)1m15CD13Infliximab 5 mg/kg/4 weeks\
(14.2 μg/ml blood level)2f10CD8AZA 2.3 mg/kg/day2f9UC1AZA 2.2 mg/kg/day2m18CD16AZA 1.9 mg/kg/day2f17CD3AZA 1.9 mg/kg/day2f13AIH4AZA 1 mg/kg/day2m17AIH10AZA 1.7 mg/kg/day2f16AIH12AZA 1.1 mg/kg/day2f9UC5Tacrolimus 0.23 mg/kg/day\
(4.5 ng/ml blood level)3f13CD12No IS3m15CD3No IS3f3CD3No IS3m14UC2No IS3f15UC10No IS3m12CD12No IS

Blood samples were taken in additional blood collection tubes during regularly needed blood examinations.

Peripheral blood mononuclear cells (PBMC) were separated using a Ficoll gradient separation (Biocoll Separating Solution, Biochrom-AG, Germany). After counting, PBMCs were stored in liquid nitrogen.

PBMCs (10^6^ cells/ml; 100 μl per well) were stimulated with PHA (Invitrogen, Germany; final concentration 15 μl/ml), tetanus antigen (Pharmore, Germany; final concentration 50 μl/ml), and adenovirus antigen (Institute of Virology, Ulm University Medical Center, Germany; final concentration 20 μl/ml). For PHA and tetanus antigen, we used culture medium as negative control, and for adenovirus antigen, we used HFF culture supernatant as negative control (Institute of Virology, Ulm University Medical Center, Germany; final concentration 20 μl/ml). As positive control, buffy coat cells of healthy donors were stimulated. Stimulation was performed in triplicates or at least in duplicates (dependent on available cell-counts) in 96-well flat bottom plates at 37 °C in 5% CO~2~ for 5 days. After incubation with radioactive H~3~-thymidine for 18 h (Perkin Elmer, Germany; final concentration 0.001 mCi/ml), the cells were harvested, and the incorporation in the DNA was measured in a beta counter (Microplatecounter TopCount NXT, Packard/Perkin Elmer). For each stimulated well, an index to the background count of the negative control was calculated.

From the same PBMCs, the lymphocyte subgroups were determined by flow cytometry (Navios, Beckman-Coulter) and the counts of lymphocytes (differential blood count with Sysmex; Institute for Clinical Chemistry, University of Ulm*)* and T cells (CD3+) were compared. Used antibodies for the flow cytometry are CD3-APC and CD45-Krome Orange (Beckman Coulter).

Data were collected and statistically analyzed using Excel 2013 and Word 2013 (Microsoft Office 2013). The statistical evaluation was performed via Kruskal-Wallis test and Mann-Whitney *U* test using a bilateral level of significance of *α* = 5%.

The patients were divided into three groups according to their IS medication at the time of blood taking. Group 1 was under high-level IS, meaning high doses of disease-modifying drugs (AZA, sirolimus, and tacrolimus) or any use of biologicals (adalimumab, golimumab, infliximab---which all block pro-inflammatory TNF-α---and the integrin antagonist vedolizumab) as described elsewhere \[[@CR3], [@CR9]\]. Group 2 was under low-level IS, which meant lower doses of disease-modifying drugs (for dosage distinction between high-level and low-level IS, see Additional file [1](#MOESM1){ref-type="media"}: Table S1). Group 3 was not treated with systemic IS therapy.

Results {#Sec3}
=======

The patient characteristics and immunosuppressive therapy are demonstrated in Table [2](#Tab2){ref-type="table"}. Most patients in group 1 were on long-term therapy with biologicals, and some even received a combination therapy with azathioprine (AZA), tacrolimus or sirolimus; all but 1 patient in group 2 are treated with AZA, and all in group 3 had no IS. All patients receiving infliximab therapy responded on induction therapy and received long-term infliximab treatment adjusted to their trough levels for dose or interval (Table [1](#Tab1){ref-type="table"}). Three patients with low infliximab levels received combination therapy (group 1). One patient had insufficient trough levels for the first time. None of the patients receiving AZA needed dose reduction due to reduced thiopurine methyltransferase (TPMT) enzyme activity. Most patients were in clinical remission, and only 4 patients had mild disease activity at the time of measurement.Table 2Descriptive comparison of in vitro reactivity of lymphocytesStimulation indexPHATetanus antigenAdenovirus antigenMedianQ1Q3MedianQ1Q3MedianQ1Q3Group 1 (*n* = 17)3062389554.21.612.815.35.0214.3Group 2 (*n* = 8)4424094832.71.798.162.59.990.5Group 3 (*n* = 6)962689101172.76.0192.051.013.0101.0All samples4722829784.21.724.141.15.1133.4

The counts of lymphocytes and CD3+ T cells were measured by flow cytometry and compared between the three groups (Fig. [1](#Fig1){ref-type="fig"}). The Kruskal-Wallis test showed no significant difference between the three groups for both lymphocytes and T cells. There is not even a trend towards lower counts with higher IS (Fig. [1](#Fig1){ref-type="fig"}). Only 4 patients had low lymphocyte counts compared to age-matched references, but no patient had low T cells. The stimulation indices of these 4 patients did not differ from the rest of the collective.Fig. 1Comparison of lymphocyte and T cell counts. The vertical axis shows absolute numbers of lymphocytes and T cells in G/l. The boxplots indicate Q1, median, and Q3 with the minimum and maximum as error bars. Light gray boxplots display the lymphocytes (L) and dark gray ones the T cells (T)

The stimulation indices for the three different stimulants (PHA, tetanus antigen, adenovirus antigen) in medians, 25% quartiles (Q1), and 75% quartiles (Q3) are shown in Table [2](#Tab2){ref-type="table"}.

We found lower stimulation indices in patients receiving IS than in those without IS. Even though a trend to higher reactivity in patients without IS can be seen, also, the groups with IS develop a notable reaction. However, the Kruskal-Wallis test could not show a significant difference in the small sample sizes between the three groups for the three different stimulants. Therefore, we compared all patients receiving IS (groups 1 + 2) with patients without IS (group 3) and performed Mann-Whitney *U* tests (Fig. [2a](#Fig2){ref-type="fig"}--[c](#Fig2){ref-type="fig"}). No statistical significant difference was found for PHA and adenovirus antigen, but for tetanus antigen. The statistical test results and limits of significance are depicted in Additional file [2](#MOESM2){ref-type="media"}: Table S2.Fig. 2In vitro lymphocyte reactivity after stimulation with PHA, tetanus antigen, and adenovirus antigen. Lymphocytes were stimulated in vitro with PHA (**a**), tetanus antigen (**b**), and adenovirus antigen (**c**) as described. The vertical axis shows stimulation indices which are calculated as count of stimulated cells divided through count of background. The boxplots indicate Q1, median, and Q3 with the minimum and maximum as error bars. The bracket above groups 1 and 2 with the star in **b** indicates significance compared to group 3 in Mann-Whitney *U* test with bilateral level of significance of *α* = 5%, but not in **a** and **c**

Discussion {#Sec4}
==========

Here, we show that the individual immunoreactivity in patients with IBD or AIH depending on long-term IS mono- or combo-therapy is not markedly disturbed. Indeed, one might have expected a strong difference, as immunosuppressants interact directly with T lymphocyte function.

A sufficiently functional T lymphocyte compartment in patients receiving IS is supported by three findings.

First, the blood counts of lymphocytes and T cells of the patients did not significantly differ between the three groups of high-level, low-level, and no IS.

Second, the unspecific T lymphocyte-stimulating agent PHA provoked effective proliferation in all three groups. There was no significant difference found neither in comparison of the three groups nor in comparison of all immunosuppressed patients to those without systemic IS.

Third, a specific T lymphocyte proliferation response to antigens, such as tetanus and adenovirus antigens, could be measured in patients receiving IS.

Moreover, after stimulation with adenovirus antigen, the proliferation indices showed nearly no difference at all between the three groups or in comparison of IS (groups 1 + 2) versus without IS (group 3). Indeed, group 3 is not a healthy control, but being patients in clinical remission and without any IS medication, we suggest that their immunoreactivity is very close to the one of a healthy individual.

Stimulation with tetanus antigen differs not significantly between the three groups. However, we found a trend to lower medians in patients with higher IS resulting in a significant difference in comparison of the immunosuppressed (groups 1 + 2) versus without IS (group 3).

Regarding the small number of investigated patients, we admit that we may indeed underestimate some statistical differences in these groups. However, the data are sufficient to deduct that there is a reduced but notable immunoreactivity towards different stimuli in patients with IBD or AIH under IS therapy, at least when counts of blood lymphocytes and T cells are within a normal range. In animal studies, a dependency of lymphocyte proliferation on the blood level of immunosuppressants has been demonstrated \[[@CR10], [@CR11]\]. Our patients were treated in effective doses to maintain remission of their disease, and the lymphocyte proliferation was still remarkably good.

In this study, most patients were in remission of their disease. In another study, patients with highly active colitis treated with infliximab in vitro were analyzed and a reduced T cell activation and proliferation was found \[[@CR12]\]. Thus, active disease may influence T cell response in vitro.

In a study by Salinas et al., patients with rheumatic diseases receiving anti-TNF-α treatment were vaccinated against hepatitis B and pneumococcal polysaccharides. Interestingly, they observed an increase of B cell activation after TNF blockade associated with an impaired T cell-dependent humoral immune response towards hepatitis B vaccination, whereas the T cell-independent reaction to pneumococcal polysaccharides was only modestly altered \[[@CR13]\]. It highlights that each immunosuppressant drug may provoke different immune reactions dependent on the stimulus in immunosuppressed patients.

Abnormal T cell responses to antigens are considered as a diagnostically more sensitive test of aberrant T cell function \[[@CR14]\]. As a result of repeated childhood vaccinations, a robust T cell-specific response to tetanus antigen is expected in healthy children and adolescents. Comparing the results for antigen-specific stimulation, we found considerable differences. Especially, the adenovirus antigen stimulation provoked almost the same reaction in all groups, whereas the stimulation with tetanus antigen was found to be less effective in blood samples of immunosuppressed patients. However, other studies that compared the lymphocyte proliferation after in vitro addition of different immunosuppressants found no difference between stimulation with tetanus antigen and other stimulants \[[@CR15], [@CR16]\].

Although the patients in this study received a variety of disease-modifying drugs and biologicals, we found only minor differences between these groups. The results for other drugs like mycophenolate mofetil could be less promising, as a study with mycophenolate mofetil demonstrates a dose-dependent reduction in lymphocyte proliferation \[[@CR17]\]. After treatment with AZA, which many patients in our study received, T cells seem to react well, even to suboptimal concentrations of mitogens, while cells treated with prednisolone reacted less, if the mitogen concentrations were lower \[[@CR18]\]. It was also shown that AZA impairs lymphocyte proliferation less than cyclosporine or methylprednisolone \[[@CR19]\]. A study with cats' blood demonstrated equal dose-dependent inhibition of lymphocyte proliferation after in vitro addition of six different IS drugs, not including AZA \[[@CR20]\].

Our findings of immunoreactivity in immunosuppressed patients are also supported by the fact that most live vaccinations reported in patients until yet were found to be safe and effective \[[@CR21]\]. Still, there occurred some adverse events, which makes it important to further investigate on how and when live vaccinations under IS therapy are advisable \[[@CR21]\]. Therefore, determining the individual immune competence of patients receiving IS before live vaccinations can be helpful in the process of individual risk-benefit analysis. In addition, to the in vitro lymphocyte proliferation assay for example, a negative QuantiFERON test with positive interferon control could also be used to prove a certain responsiveness of an individual patient's lymphocytes \[[@CR22]\].

Conclusions {#Sec5}
===========

In this study, we examined the individual immunoreactivity of patients with IBD or AIH under IS therapy with AZA, sirolimus, tacrolimus, and different biologicals. They showed only little differences in the reaction to stimulation with different antigens. This could implicate that patients under IS therapy with these immunosuppressants can be expected to react sufficiently to at least viral antigens. Understanding the degree of specific host immune response towards a variety of immunosuppressive drugs is important and has clinical implications. Given the lack of in vivo data on the safety and efficacy of several vaccines in the growing population of immunocompromised children and adolescents, additional research is needed to guide rational recommendations.
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Additional file 1: Table S1.Definition of high-level IS. (DOC 30 kb) Additional file 2: Table S2.Statistical tests and results. (PDF 130 kb) Additional file 3: Table S3.Raw data of lymphocyte proliferation assay shown as indices from duplicates/triplicates. (PDF 700 kb)
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